Screener / SEC EDGAR /CIK 0001114483 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Integer Holdings Corp ITGR

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What ITGR's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Apr 25, 2024, ITGR reported $0.59 per share under GAAP and $1.14 on its own adjusted basis: the adjusted number is +93% above GAAP.

ReleaseGAAP EPSAdjusted EPSGap
Apr 25, 2024 0.59 1.14 +93%
The company's words, latest release
Operating $ 39,277 $ 34,166 15.0 % income Net income $ 20,508 $ 13,065 57.0 % Diluted EPS $ 0.59 $ 0.39 51.3 % EBITDA(a) $ 65,385 $ 57,3 release
22.4 % EBITDA(a) Adjusted operating $ 62,875 $ 49,862 26.1 % income(a) Adjusted net $ 38,667 $ 29,060 33.1 % income(a) Adjusted EPS(a) $ 1.14 $ 0.87 31.0 % EBITDA, Adjusted EBITDA, release

What the company says its adjusted numbers leave out:

Adjusted net income for 2026 consists of GAAP income from continuing operations, excluding items such as amortization of intangible assets, restructuring and restructuring-related charges, acquisition and integration costs, other general expenses, and ERP implementation expenses, estimated to approximate $120 million, pre-tax. release Apr 30, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Integer Holdings Corporation Reports Third Quarter 2026 Results

Open on SEC

EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2026 Results PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026.

As previously announced, given Integer’s pending acquisition by an affiliate of investment funds managed by KKR (the “Transaction”) pursuant to the Agreement and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the Company is not providing a financial outlook and will not host a conference call to discuss its third quarter 2026 financial results. On September 29, 2026, the Company received early termination of the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026, Integer's stockholders approved the adoption of the Merger Agreement. The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of the remaining customary closing conditions specified in the Merger Agreement, including receipt of required regulatory approvals.

EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are non-GAAP financial measures. Please see (a) “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

Organic sales change is a non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information (a) regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts to the closest corresponding GAAP financial measures.

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change. Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

Adjusted net income and adjusted EPS consist of GAAP income (loss) from continuing operations and diluted EPS from continuing operations, respectively, adjusted for the following to the extent occurring during the period: (i) amortization of intangible assets, (ii) certain legal expenses; (iii) restructuring and restructuring-related charges; (iv) acquisition and integration costs; (v) other general expenses; (vi) ERP implementation, (vii) (gain) loss on equity investments; (viii) extinguishment of debt charges, (ix) debt conversion inducement expense; (x) European Union medical device regulation incremental charges; (xi) inventory step-up amortization; (xii) unusual, or infrequently occurring items; (xiii) the income tax provision (benefit) related to these adjustments and (xiv) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by adjusted weighted average shares.

The weighted average shares used to calculate diluted EPS in accordance with GAAP includes dilution, when applicable, resulting from the potential conversion of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the “Convertible Notes”). In connection with the issuance of the Convertible Notes, we entered into capped call contracts which are expected to reduce the potential dilution on our common stock in connection with any conversion of the Convertible Notes, subject to a cap. Adjusted weighted average shares consists of GAAP weighted average shares used to calculate diluted EPS, including, when applicable, dilutive common stock equivalents that were excluded from weighted average shares used to calculate diluted EPS as their inclusion would be anti- dilutive and excluding, when applicable, dilution resulting from the potential conversion of our Convertible Notes expected to be offset by the capped call contracts.

EBITDA is calculated by adding back interest expense, provision for income taxes, depreciation expense, and amortization expense from intangible assets and financing leases, to income (loss) from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (i), (viii), (xiii) and (xiv). Adjusted operating income consists of operating income adjusted for the same items listed above except for items (vii), (viii), (ix), (xiii) and (xiv).

Organic sales change is reported sales growth adjusted to remove the impact of foreign currency, the contribution of acquisitions and the strategic exit of the Portable Medical market. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue. For contribution of acquisitions, we exclude the impact on the growth rate attributable to the contribution of acquisitions in all periods where there were no comparable sales. For the strategic exit of the Portable Medical market, we exclude the impact on the growth rate attributable to Portable Medical sales for all periods presented.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: the completion of the Transaction on anticipated terms and timing, or at all, including obtaining regulatory approvals and satisfying other conditions to the completion of the Transaction; potential litigation relating to the Transaction that has been or could be instituted against the parties to the Merger Agreement, or their respective directors, managers, or officers, including the effects of any outcomes related thereto; our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; other events, conditions or developments that will or may occur in the future; and the timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are not guarantees of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and by others contained throughout this communication.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the Transaction. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that has been or could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; Parent’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Merger Agreement that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2026, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026, the Company’s definitive proxy statement filed with the SEC on September 14, 2026, as supplemented, and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.

Condensed Consolidated Balance Sheets - Unaudited October 2, December 31, (in thousands) 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 14,135 $ 17,161 Accounts receivable, net 345,072 346,079 Inventories 278,591 253,739 Contract assets 119,297 112,546 Prepaid expenses and other current 44,297 40,572 assets Total current assets 801,392 770,097 Property, plant and equipment, net 535,133 536,427 Goodwill 1,100,799 1,110,908 Other intangible assets, net 770,089 825,435 Deferred income taxes 8,938 8,994 Operating lease assets 82,586 98,437 Financing lease assets 55,491 37,109 Other long-term assets 39,509 23,170 Total assets $ 3,393,937 $ 3,410,577 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 111,003 $ 113,130 Operating lease liabilities 8,359 9,099 Accrued expenses and other current 81,763 109,812 liabilities Total current liabilities 201,125 232,041 Long-term debt 1,219,247 1,185,179 Deferred income taxes 113,596 116,327 Operating lease liabilities 67,371 81,899 Financing lease liabilities 49,577 28,578 Other long-term liabilities 16,622 19,910 Total liabilities 1,667,538 1,663,934 Stockholders’ equity: Common stock 35 35 Additional paid-in capital 761,271 771,223 Treasury stock (110,334 ) (76,872 ) Retained earnings 1,049,144 994,055 Accumulated other comprehensive 26,283 58,202 income Total stockholders’ equity 1,726,399 1,746,643 Total liabilities and stockholders’ $ 3,393,937 $ 3,410,577 equity

Condensed Consolidated Statements of Cash Flows - Unaudited (in thousands) Nine Months Cash flows from Ended operating October 2, September 26, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 55,089 $ 54,200 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 103,899 95,158 amortization Debt related charges included in 4,910 5,239 interest expense Debt conversion inducement — 46,681 expense Stock-based 17,273 17,467 compensation Non-cash fixed asset 7,141 — impairment Non-cash lease 7,283 7,583 expense Non-cash (gains) losses 1,395 (223 ) on equity investments Contingent consideration (1,179 ) (660 ) fair value adjustment Other non-cash 4,043 804 losses Deferred income 17 4,082 taxes Gain on sale of discontinued — (46 ) operations Changes in operating assets and liabilities, net of acquisitions:

Accounts (98 ) (46,793 ) receivable Inventories (28,474 ) (12,241 ) Prepaid expenses and (4,110 ) 117 other assets Contract assets (7,255 ) (2,106 ) Accounts 2,137 3,187 payable Accrued expenses and (29,421 ) (22,359 ) other liabilities Income taxes (11,589 ) (9,357 ) payable Net cash provided by 121,061 140,733 operating activities Cash flows from investing activities: Acquisition of property, plant (67,181 ) (63,555 ) and equipment Purchase of equity and (14,043 ) — other investments Acquisitions, — (170,872 ) net Other investing 126 (835 ) activities Net cash used in investing (81,098 ) (235,262 ) activities Cash flows from financing activities: Principal payments of — (657,697 ) long-term debt Proceeds from issuance of convertible — 977,500 notes, net of discount Proceeds from revolving 221,000 301,000 credit facility Payments of revolving (191,000 ) (427,000 ) credit facility Purchase of — (71,000 ) capped calls Payment of debt (38 ) (1,386 ) issuance costs Proceeds from the exercise of — 3,644 stock options Tax withholdings related to net share (10,419 ) (16,812 ) settlements of restricted stock unit awards Repurchases of (50,000 ) — common stock Principal payments on (6,558 ) (4,165 ) finance leases Other financing (5,163 ) 1,194 activities Net cash provided by (used in) (42,178 ) 105,278 financing activities Effect of foreign currency exchange (811 ) 1,652 rates on cash and cash equivalents Net increase (decrease) in (3,026 ) 12,401 cash and cash equivalents Cash and cash equivalents, 17,161 46,543 beginning of period Cash and cash equivalents, $ 14,135 $ 58,944 end of period

Income from continuing operations (GAAP) per diluted share amounts are calculated in accordance with GAAP using weighted average shares for diluted EPS. The per share amounts for the adjustments in the table (a) above and adjusted net income are calculated using adjusted weighted average shares. The following table provides a reconciliation from GAAP weighted average shares for diluted EPS to non-GAAP adjusted weighted average shares.

The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are (b) computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. Certain legal expenses associated with non-ordinary course legal matters. Amounts for the third quarter and first nine months of 2026 (c) include $0.7 million and $2.5 million, respectively, of expense incurred in connection with the Company’s defense of a securities class action lawsuit. We initiate discrete restructuring programs primarily to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs or improve profitability. Depending on the program, restructuring charges may include termination benefits, contract termination, facility closure and other exit and disposal costs. Restructuring-related expenses are directly related to the program and may include retention (d) bonuses, accelerated depreciation, consulting expense and costs to transfer manufacturing operations among our facilities. Amounts for the third quarter and first nine months of 2026 include $2.2 million and $5.0 million, respectively, relating to our global manufacturing alignment restructuring initiative. In addition, the third quarter and first nine months of 2026 includes $0.6 million and $3.0 million, respectively, related to an organizational realignment to enhance execution of our strategy through dedicated focus on growth and operational excellence. Acquisition and integration costs are incremental costs that are directly related to a business or asset acquisition. These costs may (e) include, among other things, professional, consulting and other fees, system integration costs, and fair value adjustments relating to contingent consideration. Other general expenses are discrete transactions occurring sporadically and affect period-over-period comparisons. The Company recorded fixed asset impairment charges during the third quarter and first nine months of 2026 of $1.2 million and $7.1 million, respectively, which were (f) primarily due to revised expectations regarding the future use of certain fixed assets, and expense of $2.9 million and $4.4 million, respectively, related to termination benefits from actions to align labor with manufacturing volumes. The third quarter and first nine months of 2025 include $6.2 million related to termination benefits from actions to align labor with manufacturing volumes. These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will (g) require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Expenses for 2026 were primarily included in SG&A. Amounts reflect our share of equity method investee (gains) losses (h) including unrealized appreciation/depreciation of the underlying interests of the investee. The charges represent incremental costs of complying with European (i) Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. Other adjustments include costs which impact period-to-period comparability and do not represent the underlying ongoing results of our business. For 2025 and 2026, amounts include costs associated with (j) leadership transitions, strategic projects, a stockholder activist matter, the Company’s strategic review and the Transaction, and a cyber incident. Other adjustments includes the following expenses (in millions):

Tax adjustments include changes to uncertain tax benefits and associated interest for all periods presented, and for 2026 also reflect nondeductible transaction costs. In addition, included in the (k) amount for the first nine months of 2025 is the write off of a deferred tax asset for $4.1 million related to a portion of the unamortized original issue discount due to the partial exchange of the 2028 Convertible Notes. Loss on extinguishment of debt consists of accelerated write-offs of (l) unamortized deferred debt issuance costs and discounts, which are included in interest expense. Debt conversion inducement expense relates to the partial exchange of (m) the 2028 Convertible Notes and is recorded within Other loss, net in the Condensed Consolidated Statements of Operations.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

(a) Excludes amounts included in Restructuring and restructuring-related charges. Total stock-based compensation expense less amounts included in (b) Restructuring and restructuring-related charges, ERP implementation, and Other adjustments.

Table D: Organic Sales Change Reconciliation (% Change) GAAP Impact of Impact of Non-GAAP Reported Foreign Strategic Organic Growth Currency(a) Exits and Change Acquisitions(a) QTD Change (3Q 2026 vs. 3Q 2025) Product Line Cardio & Vascular (5.1)% (0.1)% 0.1% (5.1)% Cardiac Rhythm Management & 3.9% —% —% 3.9% Neuromodulation Other Markets (49.7)% —% (28.3)% (21.4)% Total Sales (3.9)% —% (1.7)% (2.2)% YTD Change (9M 2026 vs. 9M 2025) Product Line Cardio & Vascular (2.2)% 0.2% 0.3% (2.7)% Cardiac Rhythm Management & 3.3% —% —% 3.3% Neuromodulation Other Markets (46.8)% —% (30.9)% (15.9)% Total Sales (2.0)% 0.1% (1.3)% (0.8)%

Sales growth has been adjusted to exclude the impact of foreign (a) currency exchange rate fluctuations, when applicable, and strategic exits and acquisitions.

Full text with the tables
                                                                    EXHIBIT 99.1
        Integer Holdings Corporation Reports Third Quarter 2026 Results         
PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation
(NYSE:ITGR) today announced results for the three months ended October 2, 2026.

ThirdQuarter 2026 Highlights(compared to Third Quarter 2025, except as noted)

As previously announced, given Integer’s pending acquisition by an affiliate of
investment funds managed by KKR (the “Transaction”) pursuant to the Agreement
and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong
Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the
Company is not providing a financial outlook and will not host a conference call
to discuss its third quarter 2026 financial results. On September 29, 2026, the
Company received early termination of the waiting period under the Hart-Scott-
Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026,
Integer's stockholders approved the adoption of the Merger Agreement. The
Transaction is anticipated to close by the end of 2026, subject to the
satisfaction or waiver of the remaining customary closing conditions specified
in the Merger Agreement, including receipt of required regulatory approvals.

Discussion of Product Line Third Quarter 2026 Sales
                                                                                
  Su…                                                                           
  Fi…                                                                           
  Re…                                                                           
  (d…                                                                           
  in                                                                            
  th…                                                                           
  ex…                                                                           
  per  Thr…  Oct…       Sep…                 Nine  Octo…       Sep…             
  sh…  Mon…    2,        26,          QTD    Mon…     2,        26,      YTD    
  da…  End…  2026       2025          Chan…  End…   2026       2025      Chan…  
 ────────────────────────────────────────────────────────────────────────────── 
  Op…  $     28,…    $  56,…    (50…         $     94,6…    $  165…      (42.…  
  in…                           %                                               
  In…                                                                           
  fr…  $     14,…    $  39,…    (62…         $     55,0…    $  54,…      1.6%   
  co…                           %                                               
  op…                                                                           
  Di…                                                                           
  EPS                           (61…                                            
  fr…  $     0.43    $  1.11    %            $      1.60    $  1.52      5.3%   
  co…                                                                           
  op…                                                                           
  EB…  $     61,…    $  88,…    (30…         $     194,…    $  207…      (6.3…  
                                %                                               
  Ad…  $     87,…    $  105…    (17…         $     267,…    $  296…      (9.6…  
  EB…                           %                                               
  Ad…                           (22…                                            
  op…  $     66,…    $  85,…    %            $     200,…    $  238…      (15.…  
  in…                                                                           
  Ad…                           (26…                                            
  net  $     46,…    $  63,…    %            $     142,…    $  163…      (13.…  
  in…                                                                           
  Ad…  $     1.34    $  1.79    (25…         $      4.14    $  4.64      (10.…  
  EP…                           %                                               
                                                                                
                                                                                
       EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net         
       income, and Adjusted EPS are non-GAAP financial measures. Please see     
  (a)  “Notes Regarding Non-GAAP Financial Information” for additional          
       information regarding our use of non-GAAP financial measures. Refer to   
       Tables A, B and C at the end of this release for reconciliations of      
       adjusted amounts to the closest corresponding GAAP financial measures.   
                                                                                
                                                                                
  Summ…                                                                         
  Prod…                                                                         
  Line                                                                          
  Resu…                                                                         
  (dol…  Three   Octob…            Septe…                                       
  in     Months      2,               26,            QTD               Organic  
  thou…  Ended     2026              2025            Change            Change…  
 ────────────────────────────────────────────────────────────────────────────── 
  Prod…                                                                         
  Line                                                                          
  Sales                                                                         
  Card…                                                                         
  &      $       263,0…    $       277,1…            (5.1)%            (5.1)%   
  Vasc…                                                                         
  Card…                                                                         
  Rhyt…                                                                         
  Mana…          175,8…            169,1…            3.9%              3.9%     
  &                                                                             
  Neur…                                                                         
  Other          10,750            21,386            (49.7…            (21.4)%  
  Mark…                                                                         
  Total  $       449,6…    $       467,6…            (3.9)%            (2.2)%   
  Sales                                                                         
         Nine                                                                   
         Months                                                                 
         Ended                                                                  
         Octob…            Septe…            YTD               Organ…           
         2,                26,               Change            Chang…           
         2026              2025                                                 
  Prod…                                                                         
  Line                                                                          
  Sales                                                                         
  Card…                                              (2.2)                      
  &      $       805,1…    $       822,8…            %                 (2.7) %  
  Vasc…                                                                         
  Card…                                                                         
  Rhyt…                                                                         
  Mana…          517,8…            501,4…            3.3%              3.3%     
  &                                                                             
  Neur…                                                                         
  Other          30,423            57,203            (46.8)            (15.9)   
  Mark…                                              %                 %        
  Total  $       1,353…    $       1,381…            (2.0)             (0.8) %  
  Sales                                              %                          
                                                                                
                                                                                
       Organic sales change is a non-GAAP financial measure. Please see “Notes  
       Regarding Non-GAAP Financial Information” for additional information     
  (a)  regarding our use of non-GAAP financial measures and refer to Table D    
       at the end of this release for a reconciliation of these amounts to the  
       closest corresponding GAAP financial measures.                           
                                                                                
About Integer ®

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device
contract development and manufacturing organizations (CDMOs) in the world,
serving the cardio and vascular, neuromodulation, and cardiac rhythm management
markets. As a strategic partner of choice, we advance the goals of our medical
device customers through industry-leading engineering and manufacturing, with a
relentless commitment to quality, service, and innovation. The company's brands
include Greatbatch Medical® and Lake Region Medical®. Additional information is
available at www.integer.net.

Investor Relations:

Kristen Stewart
551-337-3973
[email protected]

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted
accounting principles in the United States of America (“GAAP”), we provide
adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation
and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and
organic sales change. Unless otherwise indicated, all financial metrics
presented reflect continuing operations only.

Adjusted net income and adjusted EPS consist of GAAP income (loss) from
continuing operations and diluted EPS from continuing operations, respectively,
adjusted for the following to the extent occurring during the period: (i)
amortization of intangible assets, (ii) certain legal expenses; (iii)
restructuring and restructuring-related charges; (iv) acquisition and
integration costs; (v) other general expenses; (vi) ERP implementation, (vii)
(gain) loss on equity investments; (viii) extinguishment of debt charges, (ix)
debt conversion inducement expense; (x) European Union medical device regulation
incremental charges; (xi) inventory step-up amortization; (xii) unusual, or
infrequently occurring items; (xiii) the income tax provision (benefit) related
to these adjustments and (xiv) certain tax items that are outside the normal tax
provision for the period. Adjusted EPS is calculated by dividing adjusted net
income by adjusted weighted average shares.

The weighted average shares used to calculate diluted EPS in accordance with
GAAP includes dilution, when applicable, resulting from the potential conversion
of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the
“Convertible Notes”). In connection with the issuance of the Convertible Notes,
we entered into capped call contracts which are expected to reduce the potential
dilution on our common stock in connection with any conversion of the
Convertible Notes, subject to a cap. Adjusted weighted average shares consists
of GAAP weighted average shares used to calculate diluted EPS, including, when
applicable, dilutive common stock equivalents that were excluded from weighted
average shares used to calculate diluted EPS as their inclusion would be anti-
dilutive and excluding, when applicable, dilution resulting from the potential
conversion of our Convertible Notes expected to be offset by the capped call
contracts.

EBITDA is calculated by adding back interest expense, provision for income
taxes, depreciation expense, and amortization expense from intangible assets and
financing leases, to income (loss) from continuing operations, which is the most
directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA
plus adding back stock-based compensation and the same adjustments as listed
above except for items (i), (viii), (xiii) and (xiv). Adjusted operating income
consists of operating income adjusted for the same items listed above except for
items (vii), (viii), (ix), (xiii) and (xiv).

Organic sales change is reported sales growth adjusted to remove the impact of
foreign currency, the contribution of acquisitions and the strategic exit of the
Portable Medical market. To calculate the impact of foreign currency on sales
growth rates, we convert any sale made in a foreign currency by converting
current period sales into prior period sales using the exchange rate in effect
at that time and then compare the two, negating any effect foreign currency had
on our transactional revenue. For contribution of acquisitions, we exclude the
impact on the growth rate attributable to the contribution of acquisitions in
all periods where there were no comparable sales. For the strategic exit of the
Portable Medical market, we exclude the impact on the growth rate attributable
to Portable Medical sales for all periods presented.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA,
adjusted EBITDA, adjusted operating income, and organic sales change, provides
important supplemental information to management and investors seeking to
understand the financial and business trends relating to our financial condition
and results of operations. In addition to the performance measures identified
above, we believe that net total debt and leverage ratio provide meaningful
measures of liquidity and a useful basis for assessing our ability to fund our
activities, including the financing of acquisitions and debt repayments. Net
total debt is calculated as total principal amount of debt outstanding less cash
and cash equivalents. We calculate leverage ratio as net total debt divided by
adjusted EBITDA for the trailing 4 quarters.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this communication and other written and
oral statements made from time to time by us and our representatives are not
statements of historical or current fact. As such, they are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended and
are subject to the safe harbor created thereby under the Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on
our current expectations, and these statements are subject to known and unknown
risks, uncertainties and assumptions. Forward-looking statements include, but
are not limited to, statements relating to: the completion of the Transaction on
anticipated terms and timing, or at all, including obtaining regulatory
approvals and satisfying other conditions to the completion of the Transaction;
potential litigation relating to the Transaction that has been or could be
instituted against the parties to the Merger Agreement, or their respective
directors, managers, or officers, including the effects of any outcomes related
thereto; our goals, plans, and strategic initiatives; long-term growth
prospects; maximizing value for our stockholders; other events, conditions or
developments that will or may occur in the future; and the timing of any of the
foregoing. You can identify forward-looking statements by terminology such as
“may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,”
“assume,” “potential” or “continue” or variations or the negative counterparts
of these terms or other comparable terminology. These statements are only
predictions and are not guarantees of future performance, and investors should
not place undue reliance on forward-looking statements as predictive of future
results. Actual events or results may differ materially from those stated or
implied by these forward-looking statements. In evaluating these statements and
our prospects, you should carefully consider the factors set forth below. All
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by these cautionary factors and by
others contained throughout this communication.

Forward-looking statements by their nature address matters that are, to
different degrees, uncertain, such as statements regarding the Transaction. All
such forward-looking statements are based upon current plans, estimates,
expectations, opportunities and ambitions that are subject to risks,
uncertainties, assumptions, and other important factors, many of which are
beyond the control of the Company, that could cause actual results to differ
materially from those expressed in such forward-looking statements. Key factors
that could cause actual results to differ materially include, but are not
limited to, the expected timing and likelihood of completion of the Transaction,
including the timing, receipt and terms and conditions of any required
governmental and regulatory approvals; the occurrence of any event, change or
other circumstances that could give rise to the termination of the Transaction;
the risk that the parties may not be able to satisfy the conditions to the
Transaction in a timely manner or at all; risks related to disruption of
management time from ongoing business operations due to the Transaction; the
risk that any announcements relating to the Transaction could have adverse
effects on the market price of the Company’s common stock; the risk that the
Transaction and its announcement could have an adverse effect on the parties’
business relationships and business generally, including the ability of the
Company to retain customers and retain and hire key personnel and maintain
relationships with their suppliers and customers, and on their operating results
and businesses generally; the risk of unforeseen or unknown liabilities;
customer, regulatory and other stakeholder approvals and support; the risk of
unexpected future capital expenditures; the risk of potential litigation
relating to the Transaction that has been or could be instituted against the
Company or its directors and/or officers; the risk associated with third-party
contracts containing material consent, anti-assignment, transfer or other
provisions that may be related to the Transaction which are not waived or
otherwise satisfactorily resolved; significant costs, or expenses incurred in
connection with the Transaction; Parent’s ability to obtain the necessary
financing arrangements set forth in the commitment letters received in
connection with the Transaction; certain restrictions contained in the Merger
Agreement that may impact the Company’s ability to pursue certain business
opportunities or strategic transactions; the risk of various events that could
disrupt operations, including pandemics, epidemics or other public health crises
or severe weather (such as droughts, floods, avalanches and earthquakes),
cybersecurity attacks, security threats and governmental response to them, and
technological changes; the risks of labor disputes, changes in labor costs and
labor difficulties; and the risks resulting from other effects of industry,
market, economic, legal or legislative, political or regulatory conditions
outside of the Company’s control. All such factors are difficult to predict and
are beyond our control, including those detailed in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2025, which was filed with
the Securities and Exchange Commission (the “SEC”) on February 23, 2026, the
Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 3,
2026, which was filed with the SEC on August 4, 2026, the Company’s definitive
proxy statement filed with the SEC on September 14, 2026, as supplemented, and
other documents subsequently filed by the Company with the SEC. The Company’s
forward-looking statements are based on assumptions that the Company believes to
be reasonable but that may not prove to be accurate. Other unpredictable factors
not discussed in this communication could also have material adverse effects on
forward-looking statements. The Company does not assume an obligation to update
any forward-looking statements, except as required by applicable law. These
forward-looking statements speak only as of the date hereof.
                                                                                
  Condensed Consolidated Balance                                                
  Sheets - Unaudited                       October 2,          December 31,     
  (in thousands)                                 2026                  2025     
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets:                                                               
  Cash and cash equivalents             $      14,135       $        17,161     
  Accounts receivable, net                    345,072               346,079     
  Inventories                                 278,591               253,739     
  Contract assets                             119,297               112,546     
  Prepaid expenses and other current           44,297                40,572     
  assets                                                                        
  Total current assets                        801,392               770,097     
  Property, plant and equipment, net          535,133               536,427     
  Goodwill                                  1,100,799             1,110,908     
  Other intangible assets, net                770,089               825,435     
  Deferred income taxes                         8,938                 8,994     
  Operating lease assets                       82,586                98,437     
  Financing lease assets                       55,491                37,109     
  Other long-term assets                       39,509                23,170     
  Total assets                          $   3,393,937       $     3,410,577     
  LIABILITIES AND STOCKHOLDERS’ EQUITY                                          
  Current liabilities:                                                          
  Accounts payable                      $     111,003       $       113,130     
  Operating lease liabilities                   8,359                 9,099     
  Accrued expenses and other current           81,763               109,812     
  liabilities                                                                   
  Total current liabilities                   201,125               232,041     
  Long-term debt                            1,219,247             1,185,179     
  Deferred income taxes                       113,596               116,327     
  Operating lease liabilities                  67,371                81,899     
  Financing lease liabilities                  49,577                28,578     
  Other long-term liabilities                  16,622                19,910     
  Total liabilities                         1,667,538             1,663,934     
  Stockholders’ equity:                                                         
  Common stock                                     35                    35     
  Additional paid-in capital                  761,271               771,223     
  Treasury stock                             (110,334  )            (76,872  )  
  Retained earnings                         1,049,144               994,055     
  Accumulated other comprehensive              26,283                58,202     
  income                                                                        
  Total stockholders’ equity                1,726,399             1,746,643     
  Total liabilities and stockholders’   $   3,393,937       $     3,410,577     
  equity                                                                        
                                                                                
                                                                                
  Cond…                                                                         
  Cons…                                                                         
  Stat…                                                                         
  of                                                                            
  Oper…                                                                         
  -                                                                             
  Unau…                                                                         
  (in                                                                           
  thou…                                                                         
  exce…                                                                         
  per    Three   Octob…          Septe…       Nine     Octob…       Septem…     
  share  Months      2,             26,       Months       2,           26,     
  data)  Ended     2026            2025       Ended      2026          2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Sales  $       449,6…       $  467,6…       $        1,353…    $  1,381,…     
  Cost                                                                          
  of             348,1…          341,5…                1,029…       1,005,…     
  sales                                                                         
  Gross          101,5…          126,1…                324,0…       375,630     
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Sell…                                                                         
  gene…          54,147          50,451                170,5…       154,534     
  and                                                                           
  admi…                                                                         
  Rese…                                                                         
  deve…          13,528          10,949                41,049        39,390     
  and                                                                           
  engi…                                                                         
  Rest…                                                                         
  and             5,677           8,321                17,886        16,377     
  other                                                                         
  char…                                                                         
  Total                                                                         
  oper…          73,352          69,721                229,4…       210,301     
  expe…                                                                         
  Oper…          28,209          56,439                94,606       165,329     
  inco…                                                                         
  Inte…           9,701           9,367                29,570        33,926     
  expe…                                                                         
  (Gai…                                                                         
  loss                                                                          
  on                (31  )          (50  )              1,395          (223  )  
  equi…                                                                         
  inve…                                                                         
  Other                                                                         
  loss,           1,027           1,130                 2,487        53,037     
  net                                                                           
  Inco…                                                                         
  from                                                                          
  cont…          17,512          45,992                61,154        78,589     
  oper…                                                                         
  befo…                                                                         
  taxes                                                                         
  Prov…                                                                         
  (ben…                                                                         
  for             2,534           6,314                 6,065        24,367     
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  from           14,978          39,678                55,089        54,222     
  cont…                                                                         
  oper…                                                                         
  Loss                                                                          
  from                                                                          
  disc…                                                                         
  oper…               —               —                     —           (22  )  
  net                                                                           
  of                                                                            
  tax                                                                           
  Net    $       14,978       $  39,678       $        55,089    $   54,200     
  inco…                                                                         
  Basic                                                                         
  earn…                                                                         
  per                                                                           
  shar…                                                                         
  Inco…                                                                         
  from   $         0.44       $    1.13       $          1.62    $     1.56     
  cont…                                                                         
  oper…                                                                         
  Loss                                                                          
  from   $            —       $       —       $             —    $        —     
  disc…                                                                         
  oper…                                                                         
  Basic                                                                         
  earn…  $         0.44       $    1.13       $          1.62    $     1.56     
  per                                                                           
  share                                                                         
  Dilu…                                                                         
  earn…                                                                         
  per                                                                           
  shar…                                                                         
  Inco…                                                                         
  from   $         0.43       $    1.11       $          1.60    $     1.52     
  cont…                                                                         
  oper…                                                                         
  Loss                                                                          
  from   $            —       $       —       $             —    $        —     
  disc…                                                                         
  oper…                                                                         
  Dilu…                                                                         
  earn…  $         0.43       $    1.11       $          1.60    $     1.52     
  per                                                                           
  share                                                                         
  Weig…                                                                         
  aver…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic          34,027          35,081                34,106        34,689     
  Dilu…          34,604          35,608                34,394        35,755     
                                                                                
                                                                                
  Condensed                                                                     
  Consolidated                                                                  
  Statements of                                                                 
  Cash Flows -                                                                  
  Unaudited                                                                     
  (in thousands)   Nine Months                                                  
  Cash flows from  Ended                                                        
  operating        October 2,                       September 26,               
  activities:      2026                             2025                        
 ────────────────────────────────────────────────────────────────────────────── 
  Net income       $                   55,089       $                54,200     
  Adjustments to                                                                
  reconcile net                                                                 
  income to                                                                     
  net cash                                                                      
  provided by                                                                   
  operating                                                                     
  activities:                                                                   
  Depreciation                                                                  
  and                                 103,899                        95,158     
  amortization                                                                  
  Debt related                                                                  
  charges                                                                       
  included in                           4,910                         5,239     
  interest                                                                      
  expense                                                                       
  Debt conversion                                                               
  inducement                                —                        46,681     
  expense                                                                       
  Stock-based                          17,273                        17,467     
  compensation                                                                  
  Non-cash fixed                                                                
  asset                                 7,141                             —     
  impairment                                                                    
  Non-cash lease                        7,283                         7,583     
  expense                                                                       
  Non-cash                                                                      
  (gains) losses                        1,395                          (223  )  
  on equity                                                                     
  investments                                                                   
  Contingent                                                                    
  consideration                        (1,179  )                       (660  )  
  fair value                                                                    
  adjustment                                                                    
  Other non-cash                        4,043                           804     
  losses                                                                        
  Deferred income                          17                         4,082     
  taxes                                                                         
  Gain on sale of                                                               
  discontinued                              —                           (46  )  
  operations                                                                    
  Changes in                                                                    
  operating                                                                     
  assets and                                                                    
  liabilities,                                                                  
  net of                                                                        
  acquisitions:                                                                 
                                                                                
  Accounts                                (98  )                    (46,793  )  
  receivable                                                                    
  Inventories                         (28,474  )                    (12,241  )  
  Prepaid                                                                       
  expenses and                         (4,110  )                        117     
  other assets                                                                  
  Contract assets                      (7,255  )                     (2,106  )  
  Accounts                              2,137                         3,187     
  payable                                                                       
  Accrued                                                                       
  expenses and                        (29,421  )                    (22,359  )  
  other                                                                         
  liabilities                                                                   
  Income taxes                        (11,589  )                     (9,357  )  
  payable                                                                       
  Net cash                                                                      
  provided by                         121,061                       140,733     
  operating                                                                     
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Acquisition of                                                                
  property, plant                     (67,181  )                    (63,555  )  
  and                                                                           
  equipment                                                                     
  Purchase of                                                                   
  equity and                          (14,043  )                          —     
  other                                                                         
  investments                                                                   
  Acquisitions,                             —                      (170,872  )  
  net                                                                           
  Other investing                         126                          (835  )  
  activities                                                                    
  Net cash used                                                                 
  in investing                        (81,098  )                   (235,262  )  
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Principal                                                                     
  payments of                               —                      (657,697  )  
  long-term debt                                                                
  Proceeds from                                                                 
  issuance of                                                                   
  convertible                               —                       977,500     
  notes, net of                                                                 
  discount                                                                      
  Proceeds from                                                                 
  revolving                           221,000                       301,000     
  credit facility                                                               
  Payments of                                                                   
  revolving                          (191,000  )                   (427,000  )  
  credit facility                                                               
  Purchase of                               —                       (71,000  )  
  capped calls                                                                  
  Payment of debt                         (38  )                     (1,386  )  
  issuance costs                                                                
  Proceeds from                                                                 
  the exercise of                           —                         3,644     
  stock                                                                         
  options                                                                       
  Tax                                                                           
  withholdings                                                                  
  related to net                                                                
  share                               (10,419  )                    (16,812  )  
  settlements of                                                                
  restricted                                                                    
  stock unit                                                                    
  awards                                                                        
  Repurchases of                      (50,000  )                          —     
  common stock                                                                  
  Principal                                                                     
  payments on                          (6,558  )                     (4,165  )  
  finance leases                                                                
  Other financing                      (5,163  )                      1,194     
  activities                                                                    
  Net cash                                                                      
  provided by                                                                   
  (used in)                           (42,178  )                    105,278     
  financing                                                                     
  activities                                                                    
  Effect of                                                                     
  foreign                                                                       
  currency                                                                      
  exchange                               (811  )                      1,652     
  rates on cash                                                                 
  and cash                                                                      
  equivalents                                                                   
  Net increase                                                                  
  (decrease) in                        (3,026  )                     12,401     
  cash and cash                                                                 
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents,                         17,161                        46,543     
  beginning of                                                                  
  period                                                                        
  Cash and cash                                                                 
  equivalents,     $                   14,135       $                58,944     
  end of period                                                                 
                                                                                
                                                                                
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …  T…  O…                                    Se…                              
  …  M…  2,                                    26,                              
  …  E…  2…                                    20…                              
 ────────────────────────────────────────────────────────────────────────────── 
                  N…            P…                       N…            P…       
     P…           of            D…         P…            of            D…       
                  T…            S…                       T…            S…       
  …                                                                             
  …                                                                             
  …  $   1…       $   14…       $   0.…    $   45…       $   39…       $   1.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…           12…           0.…        16…           13…           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      8…           655           0.…        181           144             —  
  …                                                                             
  …                                                                             
  …                                                                             
  …      4…           3,…           0.…        2,…           2,…           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…            82             —        1,…           1,…           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      4…           3,…           0.…        6,…           4,…           0.…  
  …                                                                             
  …      3…           3,…           0.…          —             —             —  
  …                                                                             
  …                                                                             
  …                                                                             
  …      (…  )        (24  )          —        (50  )        (39  )          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …      45            35             —        183           145             —  
  …                                                                             
  …      8…           6,…           0.…        2,…           1,…           0.…  
  …                                                                             
  …       —           779           0.…          —           107             —  
  …                                                                             
  …                                                                             
  …  $   5…       $   46…       $   1.…    $   75…       $   63…       $   1.…  
  …                                                                             
  …                                                                             
     N…                                                                         
     M…                                                                         
     E…                                                                         
     O…                                    S…                                   
     2,                                    2…                                   
     2…                                    2…                                   
                  N…            P…                       N…            P…       
     P…           of            D…         P…            of            D…       
                  T…            S…                       T…            S…       
  …                                                                             
  …                                                                             
  …  $   6…       $   55…       $   1.…    $   78…       $   54…       $   1.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      4…           38…           1.…        47…           38…           1.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      2…           2,…           0.…        292           231           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…           8,…           0.…        6,…           5,…           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…           1,…           0.…        8,…           6,…           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…           10…           0.…        6,…           4,…           0.…  
  …                                                                             
  …      1…           9,…           0.…          —             —             —  
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…           1,…           0.…        (2…  )        (1…  )          —  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …       —             —             —        867           685           0.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …       —             —             —        46…           46…           1.…  
  …                                                                             
  …                                                                             
  …                                                                             
  …      3…           307           0.…        695           549           0.…  
  …                                                                             
  …      1…           13…           0.…        3,…           2,…           0.…  
  …                                                                             
  …       —           1,…           0.…          —           4,…           0.…  
  …                                                                             
  …                                                                             
  …  $   1…       $   14…       $   4.…    $   19…       $   16…       $   4.…  
  …                                                                             
  …                                                                             
                                                                                
                                                                                
       Income from continuing operations (GAAP) per diluted share amounts are   
       calculated in accordance with GAAP using weighted average shares for     
       diluted EPS.  The per share amounts for the adjustments in the table     
  (a)  above and adjusted net income are calculated using adjusted weighted     
       average shares. The following table provides a reconciliation from GAAP  
       weighted average shares for diluted EPS to non-GAAP adjusted weighted    
       average shares.                                                          
                                                                                
                                                                                
                  Three                                                         
                 Months                        Nine Months                      
                  Ended        September             Ended        September     
             October 2,              26,        October 2,              26,     
                   2026             2025              2026             2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Weighted                                                                      
  average                                                                       
  shares                                                                        
  for            34,604           35,608            34,394           35,755     
  diluted                                                                       
  EPS                                                                           
  (GAAP)                                                                        
  Less:                                                                         
  2028                                                                          
  Converti…                                                                     
  Notes            (244  )          (261  )            (90  )          (430  )  
  capped                                                                        
  call                                                                          
  options                                                                       
  impact                                                                        
  Adjusted                                                                      
  weighted                                                                      
  average        34,360           35,347            34,304           35,325     
  shares                                                                        
  (non-GAA…                                                                     
                                                                                
                                                                                
       The difference between pre-tax and net of tax amounts is the estimated   
       tax impact related to the respective adjustment. Net of tax amounts are  
  (b)  computed using a 21% U.S. tax rate, and the statutory tax rates          
       applicable in foreign tax jurisdictions, as adjusted for the existence   
       of net operating losses (“NOLs”). Expenses that are not deductible for   
       tax purposes (i.e. permanent tax differences) are added back at 100%.    
       Certain legal expenses associated with non-ordinary course legal         
       matters. Amounts for the third quarter and first nine months of 2026     
  (c)  include $0.7 million and $2.5 million, respectively, of expense          
       incurred in connection with the Company’s defense of a securities class  
       action lawsuit.                                                          
       We initiate discrete restructuring programs primarily to realign         
       resources to better serve our customers and markets, improve             
       operational efficiency and capabilities, and lower operating costs or    
       improve profitability. Depending on the program, restructuring charges   
       may include termination benefits, contract termination, facility         
       closure and other exit and disposal costs. Restructuring-related         
       expenses are directly related to the program and may include retention   
  (d)  bonuses, accelerated depreciation, consulting expense and costs to       
       transfer manufacturing operations among our facilities. Amounts for the  
       third quarter and first nine months of 2026 include $2.2 million and     
       $5.0 million, respectively, relating to our global manufacturing         
       alignment restructuring initiative. In addition, the third quarter and   
       first nine months of 2026 includes $0.6 million and $3.0 million,        
       respectively, related to an organizational realignment to enhance        
       execution of our strategy through dedicated focus on growth and          
       operational excellence.                                                  
       Acquisition and integration costs are incremental costs that are         
       directly related to a business or asset acquisition. These costs may     
  (e)  include, among other things, professional, consulting and other fees,    
       system integration costs, and fair value adjustments relating to         
       contingent consideration.                                                
       Other general expenses are discrete transactions occurring sporadically  
       and affect period-over-period comparisons. The Company recorded fixed    
       asset impairment charges during the third quarter and first nine months  
       of 2026 of $1.2 million and $7.1 million, respectively, which were       
  (f)  primarily due to revised expectations regarding the future use of        
       certain fixed assets, and expense of $2.9 million and $4.4 million,      
       respectively, related to termination benefits from actions to align      
       labor with manufacturing volumes. The third quarter and first nine       
       months of 2025 include $6.2 million related to termination benefits      
       from actions to align labor with manufacturing volumes.                  
       These adjustments represent direct and incremental costs incurred in     
       connection with our implementation of a new global enterprise resource   
       planning ("ERP") solution and related IT transition costs. An            
       implementation of this scale is a significant undertaking and will       
  (g)  require substantial time and attention of management and key employees.  
       The associated costs do not represent normal and recurring operating     
       expenses and will be inconsistent in amounts and frequency making it     
       difficult to contribute to a meaningful evaluation of our operating      
       performance. Expenses for 2026 were primarily included in SG&A.          
       Amounts reflect our share of equity method investee (gains) losses       
  (h)  including unrealized appreciation/depreciation of the underlying         
       interests of the investee.                                               
       The charges represent incremental costs of complying with European       
  (i)  Union medical device regulations for previously registered products and  
       primarily include charges for contractors supporting the project and     
       other direct third-party expenses.                                       
       Other adjustments include costs which impact period-to-period            
       comparability and do not represent the underlying ongoing results of     
       our business. For 2025 and 2026, amounts include costs associated with   
  (j)  leadership transitions, strategic projects, a stockholder activist       
       matter, the Company’s strategic review and the Transaction, and a cyber  
       incident. Other adjustments includes the following expenses (in          
       millions):                                                               
                                                                                
                                                                                
           Three     October       Septemb…    Nine      October       Septem…  
           Months         2,            26,    Months         2,           26,  
           Ended        2026           2025    Ended        2026          2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Leader…                                                                       
  transi…  $               —    $       1.0    $             1.5    $      1.7  
  costs                                                                         
  Strate…                1.8            0.7                  2.6           2.1  
  projec…                                                                       
  Stockh…                                                                       
  activi…                0.1              —                  3.9             —  
  matter                                                                        
  Strate…                                                                       
  review                 6.9              —                  8.2             —  
  and                                                                           
  Transa…                                                                       
  Cyber                                                                         
  incide…                0.5              —                  1.2             —  
  costs                                                                         
                                                                                
                                                                                
       Tax adjustments include changes to uncertain tax benefits and            
       associated interest for all periods presented, and for 2026 also         
       reflect nondeductible transaction costs. In addition, included in the    
  (k)  amount for the first nine months of 2025 is the write off of a deferred  
       tax asset for $4.1 million related to a portion of the unamortized       
       original issue discount due to the partial exchange of the 2028          
       Convertible Notes.                                                       
       Loss on extinguishment of debt consists of accelerated write-offs of     
  (l)  unamortized deferred debt issuance costs and discounts, which are        
       included in interest expense.                                            
       Debt conversion inducement expense relates to the partial exchange of    
  (m)  the 2028 Convertible Notes and is recorded within Other loss, net in     
       the Condensed Consolidated Statements of Operations.                     
                                                                                
Please see “Notes Regarding Non-GAAP Financial Information” for additional
information regarding our use of non-GAAP financial measures.
                                                                                
  Table                                                                         
  B:                                                                            
  Adjust…                                                                       
  Operat…                                                                       
  Income                                                                        
  Reconc…  Three     October       Septemb…    Nine      October       Septem…  
  (in      Months         2,            26,    Months         2,           26,  
  thousa…  Ended        2026           2025    Ended        2026          2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Operat…                                                                       
  income   $          28,209    $    56,439    $          94,606    $  165,329  
  (GAAP)                                                                        
  Adjust…                                                                       
  Amorti…                                                                       
  of                  15,749         16,249               47,716        47,220  
  intang…                                                                       
  assets                                                                        
  Certain                                                                       
  legal                  828            181                2,967           292  
  expens…                                                                       
  Restru…                                                                       
  and                  4,666          2,749               10,911         6,426  
  restru…                                                                       
  charges                                                                       
  Acquis…                                                                       
  and                    102          1,372                1,717         8,121  
  integr…                                                                       
  costs                                                                         
  Other                                                                         
  general              4,176          6,247               12,322         6,253  
  expens…                                                                       
  ERP                  3,947              —               12,221             —  
  implem…                                                                       
  Medical                                                                       
  device                  45            183                  389           695  
  regula…                                                                       
  Other                8,568          2,476               17,485         3,749  
  adjust…                                                                       
  Adjust…                                                                       
  operat…  $          66,290    $    85,896    $         200,334    $  238,085  
  income                                                                        
  (non-G…                                                                       
                                                                                
                                                                                
  Table                                                                         
  C:                                                                            
  EBIT…                                                                         
  and                                                                           
  Adju…                                                                         
  EBIT…                                                                         
  Reco…  Three   Octob…          Septe…       Nine     Octob…       Septem…     
  (in    Months      2,             26,       Months       2,           26,     
  thou…  Ended     2026            2025       Ended      2026          2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Inco…                                                                         
  from                                                                          
  cont…  $       14,978       $  39,678       $        55,089    $   54,222     
  oper…                                                                         
  (GAA…                                                                         
  Inte…           9,701           9,367                29,570        33,926     
  expe…                                                                         
  Prov…                                                                         
  (ben…                                                                         
  for             2,534           6,314                 6,065        24,367     
  inco…                                                                         
  taxes                                                                         
  Depr…          16,697          15,562                50,783        44,588     
  Amor…                                                                         
  of                                                                            
  inta…                                                                         
  asse…          17,653          17,478                53,116        50,570     
  and                                                                           
  fina…                                                                         
  leas…                                                                         
  EBIT…          61,563          88,399                194,6…       207,673     
  (non…                                                                         
  Stoc…           4,052           4,341                13,886        16,691     
  comp…                                                                         
  Cert…                                                                         
  legal             828             181                 2,967           292     
  expe…                                                                         
  Rest…                                                                         
  and             4,666           2,749                10,911         6,426     
  rest…                                                                         
  char…                                                                         
  Acqu…                                                                         
  and               102           1,372                 1,717         8,121     
  inte…                                                                         
  costs                                                                         
  Other                                                                         
  gene…           4,176           6,247                12,322         6,253     
  expe…                                                                         
  ERP             3,947               —                12,221             —     
  impl…                                                                         
  (Gai…                                                                         
  loss                                                                          
  on                (31  )          (50  )              1,395          (223  )  
  equi…                                                                         
  inve…                                                                         
  Debt                                                                          
  conv…               —               —                     —        46,681     
  indu…                                                                         
  expe…                                                                         
  Medi…                                                                         
  devi…              45             183                   389           695     
  regu…                                                                         
  Other           8,568           2,476                17,485         3,749     
  adju…                                                                         
  Adju…                                                                         
  EBIT…  $       87,916       $  105,8…       $        267,9…    $  296,358     
  (non…                                                                         
                                                                                
                                                                                
  (a)  Excludes amounts included in Restructuring and restructuring-related     
       charges.                                                                 
       Total stock-based compensation expense less amounts included in          
  (b)  Restructuring and restructuring-related charges, ERP implementation,     
       and Other adjustments.                                                   
                                                                                
                                                                                
  Table D: Organic                                                              
  Sales Change                                                                  
  Reconciliation (%                                                             
  Change)                                                                       
                        GAAP        Impact of      Impact of          Non-GAAP  
                        Reported    Foreign        Strategic          Organic   
                        Growth      Currency(a)    Exits and          Change    
                                                   Acquisitions(a)              
  QTD Change (3Q 2026                                                           
  vs. 3Q 2025)                                                                  
  Product Line                                                                  
  Cardio & Vascular     (5.1)%      (0.1)%         0.1%               (5.1)%    
  Cardiac Rhythm                                                                
  Management &          3.9%        —%             —%                 3.9%      
  Neuromodulation                                                               
  Other Markets         (49.7)%     —%             (28.3)%            (21.4)%   
  Total Sales           (3.9)%      —%             (1.7)%             (2.2)%    
  YTD Change (9M 2026                                                           
  vs. 9M 2025)                                                                  
  Product Line                                                                  
  Cardio & Vascular     (2.2)%      0.2%           0.3%               (2.7)%    
  Cardiac Rhythm                                                                
  Management &          3.3%        —%             —%                 3.3%      
  Neuromodulation                                                               
  Other Markets         (46.8)%     —%             (30.9)%            (15.9)%   
  Total Sales           (2.0)%      0.1%           (1.3)%             (0.8)%    
                                                                                
                                                                                
       Sales growth has been adjusted to exclude the impact of foreign          
  (a)  currency exchange rate fluctuations, when applicable, and strategic      
       exits and acquisitions.                                                  
                                                                                
                                                                            
  Table E: Net Total Debt Reconciliation     October 2,       December 31,  
  (in thousands)                                   2026               2025  
 ────────────────────────────────────────────────────────────────────────── 
  Total debt                              $   1,219,247    $     1,185,179  
  Add: Debt discounts and deferred               18,037             22,105  
  issuance costs included in Total debt                                     
  Total principal amount of debt              1,237,284          1,207,284  
  outstanding                                                               
  Less: Cash and cash equivalents                14,135             17,161  
  Net Total Debt (Non-GAAP)               $   1,223,149    $     1,190,123  
                                                                            

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ITGR/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.